Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2021 07:00 ET | Source: IGM Biosciences

IGM Biosciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference

MOUNTAIN VIEW, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
May 06, 2021 16:07 ET | Source: IGM Biosciences

IGM Biosciences Announces First Quarter 2021 Financial Results and Provides Corporate Update

– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – MOUNTAIN...
April 27, 2021 07:00 ET | Source: IGM Biosciences

IGM Biosciences to Present at the Truist Securities Life Sciences Summit

MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
April 12, 2021 07:00 ET | Source: IGM Biosciences

IGM Biosciences Appoints George Gauthier as Chief Commercial Officer

MOUNTAIN VIEW, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
March 30, 2021 16:17 ET | Source: IGM Biosciences

IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – – Company to...
March 24, 2021 07:00 ET | Source: IGM Biosciences

IGM Biosciences to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 30, 2021

MOUNTAIN VIEW, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
March 15, 2021 07:00 ET | Source: IGM Biosciences

IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer

MOUNTAIN VIEW, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGM), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...
February 05, 2021 07:00 ET | Source: IGM Biosciences

IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
January 11, 2021 18:00 ET | Source: IGM Biosciences

IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

MOUNTAIN VIEW, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced that it has entered into an exclusive license agreement with Medivir AB (Nasdaq...
January 07, 2021 07:00 ET | Source: IGM Biosciences

IGM Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...